Cargando…
Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma
Amplification of MDM2 on supernumerary chromosomes is a common mechanism of P53 inactivation across tumors. Here, we investigated the impact of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes in liposarcoma. Three independent regulatory circuits predominate in aggressive,...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363746/ https://www.ncbi.nlm.nih.gov/pubmed/37492096 http://dx.doi.org/10.1016/j.xgen.2023.100321 |
_version_ | 1785076699578236928 |
---|---|
author | Bevill, Samantha M. Casaní-Galdón, Salvador El Farran, Chadi A. Cytrynbaum, Eli G. Macias, Kevin A. Oldeman, Sylvie E. Oliveira, Kayla J. Moore, Molly M. Hegazi, Esmat Adriaens, Carmen Najm, Fadi J. Demetri, George D. Cohen, Sonia Mullen, John T. Riggi, Nicolò Johnstone, Sarah E. Bernstein, Bradley E. |
author_facet | Bevill, Samantha M. Casaní-Galdón, Salvador El Farran, Chadi A. Cytrynbaum, Eli G. Macias, Kevin A. Oldeman, Sylvie E. Oliveira, Kayla J. Moore, Molly M. Hegazi, Esmat Adriaens, Carmen Najm, Fadi J. Demetri, George D. Cohen, Sonia Mullen, John T. Riggi, Nicolò Johnstone, Sarah E. Bernstein, Bradley E. |
author_sort | Bevill, Samantha M. |
collection | PubMed |
description | Amplification of MDM2 on supernumerary chromosomes is a common mechanism of P53 inactivation across tumors. Here, we investigated the impact of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes in liposarcoma. Three independent regulatory circuits predominate in aggressive, dedifferentiated tumors. RUNX and AP-1 family transcription factors bind mesenchymal gene enhancers. P53 and MDM2 co-occupy enhancers and promoters associated with P53 signaling. When highly expressed, MDM2 also binds thousands of P53-independent growth and stress response genes, whose promoters engage in multi-way topological interactions. Overexpressed MDM2 concentrates within nuclear foci that co-localize with PML and YY1 and could also contribute to P53-independent phenotypes associated with supraphysiologic MDM2. Importantly, we observe striking cell-to-cell variability in MDM2 copy number and expression in tumors and models. Whereas liposarcoma cells are generally sensitive to MDM2 inhibitors and their combination with pro-apoptotic drugs, MDM2-high cells tolerate them and may underlie the poor clinical efficacy of these agents. |
format | Online Article Text |
id | pubmed-10363746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103637462023-07-25 Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma Bevill, Samantha M. Casaní-Galdón, Salvador El Farran, Chadi A. Cytrynbaum, Eli G. Macias, Kevin A. Oldeman, Sylvie E. Oliveira, Kayla J. Moore, Molly M. Hegazi, Esmat Adriaens, Carmen Najm, Fadi J. Demetri, George D. Cohen, Sonia Mullen, John T. Riggi, Nicolò Johnstone, Sarah E. Bernstein, Bradley E. Cell Genom Article Amplification of MDM2 on supernumerary chromosomes is a common mechanism of P53 inactivation across tumors. Here, we investigated the impact of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes in liposarcoma. Three independent regulatory circuits predominate in aggressive, dedifferentiated tumors. RUNX and AP-1 family transcription factors bind mesenchymal gene enhancers. P53 and MDM2 co-occupy enhancers and promoters associated with P53 signaling. When highly expressed, MDM2 also binds thousands of P53-independent growth and stress response genes, whose promoters engage in multi-way topological interactions. Overexpressed MDM2 concentrates within nuclear foci that co-localize with PML and YY1 and could also contribute to P53-independent phenotypes associated with supraphysiologic MDM2. Importantly, we observe striking cell-to-cell variability in MDM2 copy number and expression in tumors and models. Whereas liposarcoma cells are generally sensitive to MDM2 inhibitors and their combination with pro-apoptotic drugs, MDM2-high cells tolerate them and may underlie the poor clinical efficacy of these agents. Elsevier 2023-05-11 /pmc/articles/PMC10363746/ /pubmed/37492096 http://dx.doi.org/10.1016/j.xgen.2023.100321 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Bevill, Samantha M. Casaní-Galdón, Salvador El Farran, Chadi A. Cytrynbaum, Eli G. Macias, Kevin A. Oldeman, Sylvie E. Oliveira, Kayla J. Moore, Molly M. Hegazi, Esmat Adriaens, Carmen Najm, Fadi J. Demetri, George D. Cohen, Sonia Mullen, John T. Riggi, Nicolò Johnstone, Sarah E. Bernstein, Bradley E. Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title | Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title_full | Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title_fullStr | Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title_full_unstemmed | Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title_short | Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma |
title_sort | impact of supraphysiologic mdm2 expression on chromatin networks and therapeutic responses in sarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363746/ https://www.ncbi.nlm.nih.gov/pubmed/37492096 http://dx.doi.org/10.1016/j.xgen.2023.100321 |
work_keys_str_mv | AT bevillsamantham impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT casanigaldonsalvador impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT elfarranchadia impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT cytrynbaumelig impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT maciaskevina impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT oldemansylviee impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT oliveirakaylaj impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT mooremollym impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT hegaziesmat impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT adriaenscarmen impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT najmfadij impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT demetrigeorged impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT cohensonia impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT mullenjohnt impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT rigginicolo impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT johnstonesarahe impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma AT bernsteinbradleye impactofsupraphysiologicmdm2expressiononchromatinnetworksandtherapeuticresponsesinsarcoma |